publication . Article . 2020

Therapeutic Drug Monitoring, CYP2C9 Genotyping and Phenotyping in the Treatment of Diabetes with Glibenclamide Products

G. I. Gorodetskaya; V. V. Arkhipov; E. S. Melnikov; T. A. Rodina;
Open Access
  • Published: 01 Jun 2020 Journal: The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products, volume 10, pages 89-95 (issn: 1991-2919, eissn: 2619-1172, Copyright policy)
  • Publisher: SCEEMP
Rational use of glybenclamide products in the treatment of patients with type 2 diabetes remains a high-priority task. The paper offers a summary of the main groups of glibenclamide drugs and describes pharmacogenetics of glybenclamide. Glibenclamide is metabolized by the enzyme cytochrome P450 2C9 (CYP2C9). Individuals with genetically determined low CYP2C9 activity are at an increased risk of hypoglycaemia. Carriers of CYP2C9*3 and CYP2C9*2 alleles tend to have higher concentrations of glybenclamide in blood and increased insulin secretion. Pharmacogenetic testing of patients and drug concentration monitoring using HPLC-MS can help reduce the risk of hypoglyce...
Persistent Identifiers
free text keywords: glibenclamide, diabetes mellitus, genotyping, phenotyping, cyp2c9, hplc-ms, therapeutic drug monitoring, Medicine (General), R5-920, Medicine, business.industry, business, Therapeutic drug monitoring, medicine.diagnostic_test, Bioequivalence, Pharmacogenetics, Drug, media_common.quotation_subject, media_common, Pharmacology, Pharmacokinetics, Glibenclamide, medicine.drug, Hypoglycemia, medicine.disease, Type 2 diabetes
Any information missing or wrong?Report an Issue